Finanzen von Seres Therapeutics Inc (MCRB)MCRBSeres Therapeutics Inc

Evaluating the bottom line, Seres Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2101.36%, while the net margin is 622.42%. These profitability ratios, combined with a Return on Equity (ROE) of -66.57%, provide a clear picture of how effectively MCRB converts its operational activities into shareholder value.

In the context of the broader market, MCRB competes directly with industry leaders such as TCRX and TIL. With a market capitalization of $52.03M, it holds a significant position in the sector. When comparing efficiency, MCRB's gross margin of 100.00% stands against TCRX's 100.00% and TIL's N/A. Such benchmarking helps identify whether Seres Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Seres Therapeutics has shown improved financial performance with a net income of $4.6 million in Q2 2026, compared to a net loss of $19.9 million in Q2 2025. The gross margin has been consistently high at 100% for the last four quarters, indicating strong profitability on its limited revenue.